ISSN: 2455-1414
Journal of Clinical Research and Ophthalmology
Perspective       Open Access      Peer-Reviewed

Trends in MacTel treatment: A vascular or neurological disease?

Hossein Ghahvehchian, Hamid Riazi-Esfahani and Masoud Mirghorbani*

Farabi Eye Hospital, Tehran University of Medical Science, Tehran, Iran
*Corresponding author: Masoud Mirghorbani, MD, MPH, Farabi Eye Hospital, Qazvin square, South Kargar Street, Tehran, Iran, Tel : +989112115615; E-mail: masoud_mirghorbani2016@yahoo.com
Received: 06 June, 2019 | Accepted: 05 July, 2019 | Published: 06 July, 2019

Cite this as

Ghahvehchian H, Esfahani HR, Mirghorbani M (2019) Trends in MacTel treatment: A vascular or neurological disease?. J Clin Res Ophthalmol 6(1): 025-027. DOI: 10.17352/2455-1414.000059

Idiopathic macular telangiectasia type 2 (MacTel) is known with temporal juxtafoveal retinal capillaries dilation and telangiectasia. The disease is most common in the fifth and sixth decades [1]. Patients often report a progressive bilateral visual loss. Macular transparency, retinal crystalline deposits, distribution of brown pigmented cells adjacent abnormal blood vessels, redistribution of macular pigment and retinal atrophy in the end stages are the findings that can be seen [1]. Subretinal neovascularization may occur in some patients and worsens the symptoms. Yannuzzi et al. classified MacTel disease based on clinical, therapeutic, and prognostic aspects: the non-proliferative phase (stage1 to 4) and the proliferative phase (stage 5) associated with development of subretinal neovascularization, however, it does not necessarily have a step-by-step pattern and CNV may appear at any stage [2]. In the primary stages, MacTel can have an intangible course with subtle signs which makes it difficult to diagnose in the classic examinations.

Our knowledge about the pathophysiology of the disease has changed over the last few years. Gass et al. first assumed that the disease was caused by vascular dysfunction and subsequent hypoperfusion, and the disease actually had a vascular base [3]; however, in histologic studies, an abnormal dilation was seen in the retinal deep plexus vascular layer and these altered areas suffered from Muller cell depletion [4]. Later studies carried out by imaging modalities such as scanning laser ophthalmoscopy and optical coherence tomography suggested a new theory that the MacTel is a neurodegenerative disorder [5]. Muller cells perform several critical functions in retina including the production of growth factors, modulation of synaptogenesis 2and angiogenesis, photoreceptor protection and neuronal permanence. These cells have an important role in the pathophysiology of the MacTel [6]. Although the causal relationship between Muller cell loss and MacTel is not proven [5], the experimental deletion of Muller cells causes to MacTel like changes in the retina including photoreceptor apoptosis, vessel dilation and telangiectasia development, and neovascularization [7].

Different types of treatment have been used for MacTel. Due to concepts about the vascular base of the disease, Anti-Vascular Endothelial Growth Factor (Anti-VEGF) was extensively used in non-proliferative and proliferative stages. Although early case reports and retrospective studies showed visual and structural gains with anti-VEGFs in non-proliferative stages [8], recent clinical trials didn't approve visual benefits [9,10]. Some temporary structural improvement such as central retinal thickness decrease was reported which had not been sustained for more than a few months. Also, in some studies, the anti-VEGF receiving groups had poorer outcomes and subsequent sequela (including vision loss more than two lines, paracentral scotomas, and subretinal neovascularization) compare to controls [11,12]. Conversely, anti-VEGF therapy had brilliant results in the proliferative disease, and a significant amount of studies consider it as the first line intervention [13,14].

Toklu et al. reported a case with good short-term outcomes of intravitreal triamcinolone injection (IVT) for non-proliferative MacTel although there is no clinical trial about IVT in this area [15]. YAG-laser doubled frequency laser therapy, indocyanine green dye-enhanced photocoagulation (ICG-DEP) and combined photodynamic therapy and intravitreal ranibizumab had also been used to treat non-proliferative disease but without promising results [16,17]. There are some studies about the benefit of laser therapy in the proliferative phase. Photodynamic therapy stabilized VA in a case series [18] and transpupillary thermotherapy completely regressed the neovascular membrane in 85% of 13 eyes [19]. However, laser photocoagulation was associated with a large parafoveal scar and profoundly impaired reading ability [20].

Some studies suggested that the vitreoretinal adhesions and tractions are responsible for anatomical macular changes in MacTel. However, it should be noted that vitreomacular traction (VMT) and epiretinal membranes (ERM) are not part of MacTel classic findings. Some studies have been reported benefits for the pars plana vitrectomy, subretinal surgery to remove the neovascular membrane, and other macular surgeries in patients with MacTel. The repair of the lamellar hole-like retinal cavities with surgical methods may be appealing and acceptable at first glance but it should be noted that the main cause of vision loss in patients, whether in the proliferative phase or in the non-proliferative phase, seems to be neurodegenerative changes and these surgical procedures may not have the desired results [21].

Resolving of the macular cystic cavities was the treatment goal of some clinical trials. Chen et al. observed that carbonic anhydrase inhibitors, especially acetazolamide, successfully improved relevant imaging markers including cystic cavities disappearance and central macular thickness reduction but these changes didn't translate to visual acuity improvement in the non-proliferative disease [22].

Rearrangement of macular carotenoid is an important sign of MacTel, particularly in the early stages, similar to what we see in the age-related macular degeneration. There are conflictual findings of the efficacy of carotenoid supplements in the MacTel and stronger randomized clinical trials are needed to investigate the role of these supplementations [23,24].

Given the new knowledge about the neurodegenerative nature of MacTel, intervention on the neural mediators can broaden our outlook on the treatment of MacTel. Ciliary neurotrophic factor (CNTF) is one of these mediators that reduced the photoreceptor degeneration in animal models [25]. The safety of NT-501, an intraocular delivery implant of CNTF, was confirmed in patients with MacTel in a prospective study after 3 years of implantation. After 48 months of follow up, a promising significant functional improvement was reported [25]. Recently, new findings have been reported on the genetic aspects of the disease. A genomic study showed a susceptible locus on chromosome 1 at 1q41-42 [27], which could be the basis for further studies and the use of gene therapy in the future.

In short, new studies on the etiology of MacTel are underway and improving our knowledge about the cellular and molecular processes, can make a big difference in the context of MacTel treatments.

  1. Charbel Issa P, Gillies MC, Chew EY, Bird AC, Heeren TFC, et al. (2013) Macular telangiectasia type 2. Prog Retin Eye Res 34: 49-77. Link: http://bit.ly/2FXnHVE
  2. Yannuzzi LA, Bardal AMC, Freund KB, Chen K-J, Eandi CM, et al. (2006) Idiopathic Macular Telangiectasia. Arch Ophthalmol 124: 450-460. Link: http://bit.ly/2RYaAIE
  3. Gass JDM, Blodi BA (1993) Idiopathic Juxtafoveolar Retinal Telangiectasis: Update of Classification and Follow-up Study. Ophthalmology 100: 1536-1546. Link: http://bit.ly/2Yz01OB
  4. Powner MB, Gillies MC, Tretiach M, Scott A, Guymer RH, et al. (2010) Perifoveal Müller Cell Depletion in a Case of Macular Telangiectasia Type 2. Ophthalmology 117: 2407-2416. Link: http://bit.ly/2XqEgzd
  5. Spaide RF, Klancnik JM, Cooney MJ (2015) Retinal Vascular Layers in Macular Telangiectasia Type 2 Imaged by Optical Coherence Tomographic AngiographyRetinal Vascular Layers in Macular Telangiectasia Type 2Retinal Vascular Layers in Macular Telangiectasia Type 2. JAMA Ophthalmology 133: 66-73.
  6. Goldman D (2014) Müller glial cell reprogramming and retina regeneration. Nature Reviews Neuroscience 15: 431-442. Link: https://go.nature.com/2KZdGew
  7. Shen W, Fruttiger M, Zhu L, Chung SH, Barnett NL, et al. (2012) Conditional Müller Cell Ablation Causes Independent Neuronal and Vascular Pathologies in a Novel Transgenic Model. The Journal of Neuroscience 32: 15715-15727. Link: http://bit.ly/309EWdK
  8. Aydoğan T, Erdoğan G, Ünlü C, Ergin A (2016) Intravitreal Bevacizumab Treatment in Type 2 Idiopathic Macular Telangiectasia. Turk J Ophthalmol 46: 270-273. Link: http://bit.ly/2XKGpd7
  9. Do DV, Bressler SB, Cassard SD, Gower EW, Tabandeh H, et al. (2014) Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization. Retina 34: 2063-2071. Link: http://bit.ly/2RWnuqf
  10. Toy BC, Koo E, Cukras C, Meyerle CB, Chew EY, et al. (2012) Treatment of Nonneovascular Idiopathic Macular Telangiectasia Type 2 with Intravitreal Ranibizumab: Results of a Phase II Clinical Trial. Retina 32: 996-1006. Link: http://bit.ly/2FUludD
  11. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, et al. (2008) Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol 122: 181-187. Link: http://bit.ly/32dwDjg
  12. Kupitz EH, Heeren TFC, Holz FG, Charbel Issa P (2015) Poor Long-Term Outcome of Anti-Vascular Endothelial Growth Factor Therapy in Nonproliferative Macular Telangiectasia Type 2. Retina 35: 2619-2626. Link: http://bit.ly/2Nzx3gu
  13. Narayanan R, Chhablani J, Sinha M, Dave V, Tyagi M, et al. (2012) Efficacy Of Anti–Vascular Endothelial Growth Factor Therapy In Subretinal Neovascularization Secondary To Macular Telangiectasia Type 2. Retina 32: 2001-2005. Link: http://bit.ly/2RWdDRm
  14. Toygar O, Guess MG, Youssef DS, Miller DM (2016) Long-Term Outcomes of Intravitreal Bevacizumab Therapy for Subretinal Neovascularization Secondary to Idiopathic Macular Telangiectasia Type 2. Retina 36: 2150-2157. Link: http://bit.ly/2XtVS1G
  15. Toklu Y, Raza S, Anayol MA, Özkan B, Koçak Altýntaþ A, et al. (2011) Comparison Between the Efficacy of Triamcinolone Acetonide and Bevacizumab in a Case with Type 2A Idiopathic Parafoveal Telangiectasia. Turk Oftalmoloji Gazetesi 41: 6-9. Link: http://bit.ly/2XyYonL
  16. Steigerwalt RD, Pascarella A, Arrico L, Librando A, Plateroti R, et al. (2012) Idiopathic juxtafoveal retinal telangiectasis and retinal macroaneurysm treated with indocyanine green dye-enhanced photocoagulation. Panminerva Med 54: 93-96. Link: http://bit.ly/2L21B8s
  17. Zehetner C, Haas G, Treiblmayr B, Kieselbach GF, Kralinger MT (2013) Reduced-Fluence Photodynamic Therapy Combined with Ranibizumab for Nonproliferative Macular Telangiectasia Type 2. Ophthalmologica 229: 195-202. Link: http://bit.ly/2LGjtVV
  18. Potter MJ, Szabo SM, Chan EY, Morris AHC (2002) Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. American Journal of Ophthalmology 133: 149-151. Link: http://bit.ly/2JpSRG6
  19. Shukla D, Singh J, Kolluru CM, Kim R, Namperumalsamy P (2004) Transpupillary thermotherapy for subfoveal neovascularization secondary to group 2A idiopathic juxtafoveolar telangiectasis. American Journal of Ophthalmology 138: 147-149. Link: http://bit.ly/2xuJBuN
  20. Vaze A, Gillies M (2016) Salient features and management options of macular telangiectasia type 2: a review and update. Expert Review of Ophthalmology 11: 429-441. Link: http://bit.ly/2xyIDxy
  21. Khodabande A, Roohipoor R, Zamani J, Mirghorbani M, Zolfaghari H, et al. (2019) Management of Idiopathic Macular Telangiectasia Type 2. Ophthalmology and Therapy 8: 155-175. Link: http://bit.ly/2Jcy9dL
  22. Chen JJ, Sohn EH, Folk JC, Mahajan VB, Kay CN, et al. (2014) Decreased Macular Thickness in Nonproliferative Macular Telangiectasia Type 2 with Oral Carbonic Anhydrase Inhibitors. Retina 34: 1400-1406. Link: http://bit.ly/2Jdat8Z
  23. Choi RY, Gorusupudi A, Wegner K, Sharifzadeh M, Gellermann W, et al. (2017) Macular Pigment Distribution Responses To High-Dose Zeaxanthin Supplementation In Patients With Macular Telangiectasia Type 2. Retina 37: 2238-2247. Link: http://bit.ly/2RUBCk2
  24. Zeimer MB, Krömer I, Spital G, Lommatzsch A, Pauleikhoff D (2010) Macular Telangiectasia: Patterns of Distribution of Macular Pigment and Response to Supplementation. Retina 30: 1282-1293. Link: http://bit.ly/30fxXAi
  25. Cayouette M, Gravel C (1997) Adenovirus-Mediated Gene Transfer of Ciliary Neurotrophic Factor Can Prevent Photoreceptor Degeneration in the Retinal Degeneration (rd) Mouse. Hum Gene Ther 8: 423-430. Link: http://bit.ly/2XsUXtN
  26. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, et al. (2015) Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2: Results From a Phase 1 Safety Trial. American Journal of Ophthalmology 159: 659-666. Link: http://bit.ly/32a1nkR
  27. Parmalee NL, Schubert C, Figueroa M, Bird AC, Peto T, et al. (2012) Identification of a potential susceptibility locus for macular telangiectasia type 2. PloS One 7: e24268. Link: http://bit.ly/2JnxVzo
© 2019 Ghahvehchian H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.